DK1286671T3 - Sammensætninger til behandling af colorektal cancer hvilke indeholder thalidomid og irinotecan - Google Patents

Sammensætninger til behandling af colorektal cancer hvilke indeholder thalidomid og irinotecan

Info

Publication number: DK1286671T3
Authority: DK; Denmark
Prior art keywords: irinotecan; treatment; compositions; thalidomide; colorectal cancers
Prior art date: 2000-05-15

Application number

DK01935372T

Other languages

Danish (da)

English (en)

Inventor

Andrew Zeitlin

Rangaswamy Govindarajan

Original Assignee

Celgene Corp

Univ Arkansas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-15

Filing date

2001-05-10

Publication date

2006-07-17

2001-05-10 Application filed by Celgene Corp, Univ Arkansas filed Critical Celgene Corp

2006-07-17 Application granted granted Critical

2006-07-17 Publication of DK1286671T3 publication Critical patent/DK1286671T3/da

Links

UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 title abstract 4
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title abstract 4
229960004768 irinotecan Drugs 0.000 title abstract 4
229960003433 thalidomide Drugs 0.000 title abstract 4
208000001333 Colorectal Neoplasms Diseases 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 2
206010009944 Colon cancer Diseases 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
230000002265 prevention Effects 0.000 abstract 2
230000002411 adverse Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicinal Preparation (AREA)

DK01935372T 2000-05-15 2001-05-10 Sammensætninger til behandling af colorektal cancer hvilke indeholder thalidomid og irinotecan DK1286671T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US20414200P	2000-05-15	2000-05-15

Publications (1)

Publication Number	Publication Date
DK1286671T3 true DK1286671T3 (da)	2006-07-17

Family

ID=22756801

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01935372T DK1286671T3 (da)	2000-05-15	2001-05-10	Sammensætninger til behandling af colorektal cancer hvilke indeholder thalidomid og irinotecan

Country Status (12)

Country	Link
US (2)	US6914067B2 (pt)
EP (1)	EP1286671B1 (pt)
JP (1)	JP4679028B2 (pt)
AT (1)	ATE322265T1 (pt)
AU (2)	AU2001261473B2 (pt)
CA (1)	CA2408710C (pt)
DE (1)	DE60118547T2 (pt)
DK (1)	DK1286671T3 (pt)
ES (1)	ES2261415T3 (pt)
NZ (1)	NZ522766A (pt)
PT (1)	PT1286671E (pt)
WO (1)	WO2001087306A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6881420B2 (en) *	2000-06-23	2005-04-19	Teva Pharmaceutical Industries Ltd.	Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
JP2005501840A (ja) *	2001-07-23	2005-01-20	エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト	癌の改良された治療のための手段および方法
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1900369A1 (en)	2002-10-15	2008-03-19	Celgene Corporation	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US7563810B2 (en)	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US7230012B2 (en) *	2002-11-14	2007-06-12	Celgene Corporation	Pharmaceutical compositions and dosage forms of thalidomide
US9006267B2 (en) *	2002-11-14	2015-04-14	Celgene Corporation	Pharmaceutical compositions and dosage forms of thalidomide
US6987012B2 (en) *	2003-06-11	2006-01-17	Ultra Biotech Limited	Biological compositions and methods for treatment of colorectal cancer
EA200600921A1 (ru) *	2003-11-06	2006-10-27	Селджин Корпорейшн	Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
KR101462825B1 (ko)	2004-05-03	2014-11-21	헤르메스 바이오사이언스, 인코포레이티드	약물 전달에 유용한 리포좀
US8658203B2 (en)	2004-05-03	2014-02-25	Merrimack Pharmaceuticals, Inc.	Liposomes useful for drug delivery to the brain
US7994186B2 (en) *	2005-04-18	2011-08-09	Kabushiki Kaisha Yakult Honsha	Pharmaceutical compositions containing camptothecins
JP2008540585A (ja) *	2005-05-19	2008-11-20	プロメティック・バイオサイエンスィズ・インコーポレーテッド	転移性メラノーマ及び他の癌を治療するための化合物、そのような化合物を含有する組成物、および治療方法
EP1946114A4 (en) *	2005-09-21	2010-05-26	Ccc Diagnostics Llc	COMPREHENSIVE DIAGNOSTIC TESTS FOR PERSONAL ANTIBODY CHEMOTHERAPY (PAC)
US20070219825A1 (en) *	2005-11-23	2007-09-20	Maetzold Derek J	Method of managing and reducing side effects associated with exposure to a drug
US7723301B2 (en) *	2007-08-29	2010-05-25	The Board Of Trustees Of The University Of Arkansas	Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same
US20090137631A1 (en) *	2007-11-22	2009-05-28	National Yang-Ming University	Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
US20120045433A1 (en) *	2010-08-17	2012-02-23	Kapil Dhingra	Combination therapy
US8709419B2 (en)	2010-08-17	2014-04-29	Hoffmann-La Roche, Inc.	Combination therapy
US9295669B2 (en)	2010-12-14	2016-03-29	Hoffman La-Roche Inc.	Combination therapy for proliferative disorders
AU2013202947B2 (en)	2012-06-13	2016-06-02	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en)	2012-06-13	2017-08-01	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies
AU2015305449B2 (en)	2014-08-22	2021-05-06	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US10098813B2 (en)	2014-09-03	2018-10-16	Sun Pharmaceutical Industries Limited	Perfusion dosage form
US11318131B2 (en)	2015-05-18	2022-05-03	Ipsen Biopharm Ltd.	Nanoliposomal irinotecan for use in treating small cell lung cancer
SG10201913073YA (en)	2015-08-20	2020-03-30	Ipsen Biopharm Ltd	Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en)	2015-08-21	2021-03-17	Ipsen Biopharm Ltd.	Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
ES3036518T3 (en)	2015-10-16	2025-09-19	Ipsen Biopharm Ltd	Stabilizing camptothecin pharmaceutical compositions
CN109069342A (zh)	2016-02-09	2018-12-21	太阳医药工业有限公司	灌注系统
RU2761953C2 (ru)	2016-11-02	2021-12-14	Ипсен Биофарм Лтд.	Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
JP7536085B2 (ja) *	2019-08-19	2024-08-19	メルスナムローゼフェンノートシャップ	Ｌｇｒ５及びｅｇｆｒに結合する抗体とトポイソメラーゼｉ阻害剤との組合せを用いる癌の治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6019790A (ja)	1983-07-14	1985-01-31	Yakult Honsha Co Ltd	新規なカンプトテシン誘導体
AU1531492A (en)	1991-02-14	1992-09-15	Rockefeller University, The	Method for controlling abnormal concentration tnf alpha in human tissues
US5629327A (en)	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US5643915A (en)	1995-06-06	1997-07-01	Andrulis Pharmaceuticals Corp.	Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5654312A (en)	1995-06-07	1997-08-05	Andrulis Pharmaceuticals	Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
WO1998037892A1 (en) *	1997-02-27	1998-09-03	Pharmacia & Upjohn Company	Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea

2001
- 2001-05-10 JP JP2001583774A patent/JP4679028B2/ja not_active Expired - Fee Related
- 2001-05-10 WO PCT/US2001/015326 patent/WO2001087306A2/en not_active Ceased
- 2001-05-10 AU AU2001261473A patent/AU2001261473B2/en not_active Ceased
- 2001-05-10 DK DK01935372T patent/DK1286671T3/da active
- 2001-05-10 AT AT01935372T patent/ATE322265T1/de active
- 2001-05-10 DE DE60118547T patent/DE60118547T2/de not_active Expired - Lifetime
- 2001-05-10 CA CA2408710A patent/CA2408710C/en not_active Expired - Fee Related
- 2001-05-10 ES ES01935372T patent/ES2261415T3/es not_active Expired - Lifetime
- 2001-05-10 NZ NZ522766A patent/NZ522766A/en not_active IP Right Cessation
- 2001-05-10 EP EP01935372A patent/EP1286671B1/en not_active Expired - Lifetime
- 2001-05-10 AU AU6147301A patent/AU6147301A/xx active Pending
- 2001-05-10 PT PT01935372T patent/PT1286671E/pt unknown
- 2001-05-14 US US09/853,619 patent/US6914067B2/en not_active Expired - Fee Related
2005
- 2005-05-11 US US11/126,315 patent/US7479499B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1286671A2 (en)	2003-03-05
EP1286671B1 (en)	2006-04-05
JP2003533483A (ja)	2003-11-11
WO2001087306A8 (en)	2002-10-03
WO2001087306A2 (en)	2001-11-22
US20050203060A1 (en)	2005-09-15
ATE322265T1 (de)	2006-04-15
AU2001261473B2 (en)	2006-09-14
PT1286671E (pt)	2006-08-31
DE60118547T2 (de)	2007-02-01
US20020035091A1 (en)	2002-03-21
HK1053975A1 (en)	2003-11-14
CA2408710C (en)	2010-01-26
CA2408710A1 (en)	2001-11-22
DE60118547D1 (de)	2006-05-18
NZ522766A (en)	2005-09-30
AU6147301A (en)	2001-11-26
US7479499B2 (en)	2009-01-20
JP4679028B2 (ja)	2011-04-27
ES2261415T3 (es)	2006-11-16
US6914067B2 (en)	2005-07-05

Publication	Publication Date	Title
PT1286671E (pt)	2006-08-31	Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan
MXPA02011218A (es)	2004-08-19	Composiciones y metodos para el tratamiento de cancer.
HK1042244A1 (zh)	2002-08-09	包含可治疗或抑制结肠息肉及结肠直肠癌的成份的nsaid与efgr激酶抑制物
NO20024610D0 (no)	2002-09-26	Synergistiske metoder og blandinger for behandling av kreft
DK1539166T3 (da)	2008-10-20	Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
NO20054988D0 (no)	2005-10-26	Preparater og metoder for behandling av cancer
WO2004052280A3 (en)	2004-08-12	Anti-angiogenic compounds and their use in cancer treatment
TW200604192A (en)	2006-02-01	Compounds and methods for inhibiting mitotic progression
EP1355563A4 (en)	2004-07-21	METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES
DK1169059T3 (da)	2006-02-27	Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
SE0102315D0 (sv)	2001-06-28	Compounds
PL373302A1 (en)	2005-08-22	Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
ATE344670T1 (de)	2006-11-15	Synergistische kombination zur behandlung von kolorektalkarzinom
MX2008015775A (es)	2009-04-17	Compuestos y composiciones para tratamiento de cancer.
WO2004028474A3 (en)	2004-07-01	Caspase inhibitors as anticancer agents
PL368271A1 (en)	2005-03-21	Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
EP1503748A4 (en)	2009-10-21	DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
UA72927C2 (uk)	2005-05-16	Композиція для лікування печінково-клітинного раку, що містить доцетаксель
MXPA05011213A (es)	2006-02-17	Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia.
MXPA03001455A (es)	2004-05-04	Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa.
WO2003072053A3 (en)	2004-09-30	Compounds for treatment of copper overload
WO2002041831A3 (en)	2002-07-18	Inositol derivatives for increasing chloride secretion and inhibiting inflammation
PL357179A1 (en)	2004-07-26	Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
EP1303300A4 (en)	2004-03-24	COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
DK1159426T3 (da)	2006-05-15	Kloning og udtryk af Haemophilus somnus transferrin-bindende proteiner